BioSpace News Archive

Kinnate Biopharma Inc., a clinical-stage precision oncology company, announced financial results for the quarter ended September 30, 2022, and recent corporate updates.

iTeos Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2022 and provided corporate highlights.

Vincerx Pharma, Inc. reported financial results for the quarter ended September 30, 2022 and provided a corporate update.

Indaptus Therapeutics, Inc., announces financial results for the third quarter ended September 30, 2022 and provides a corporate update.

RVL Pharmaceuticals plc, a specialty pharmaceutical company, announced financial results and business highlights for the three months ended September 30, 2022.

HTG Molecular Diagnostics, Inc., a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, reported financial results for the quarter ended September 30, 2022 and provided recent business highlights.

Sight Sciences, Inc., an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, reported financial results for the third quarter ended September 30, 2022.

Chinook Therapeutics, Inc. provided a business update and reported financial results for the quarter and nine months ended September 30, 2022.

Cue Biopharma, Inc. announced today the presentation of new positive data from its ongoing Phase 1 trial evaluating its lead interleukin 2 (IL-2)-based biologic, CUE-101 in combination with pembrolizumab (KEYTRUDA), as a first line therapy for patients with recurrent/metastatic HPV+ head and neck squamous cell carcinoma (HNSCC).

Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced updated overall survival (OS) results from its Phase 1/2 study evaluating GRANITE, an individualized vaccine-based immunotherapy, for the treatment of advanced solid tumors.